Entera Bio surges 40% on positive topline data for osteoporosis drug

Entera Bio

23/06/2021 14:15

** Shares of biopharmaceutical company  ENTX.O  jump nearly
40% to a three-month high at $6.27 in premarket trade 
    ** Co announces positive topline data for its osteoporosis
drug, EB613, and that the study met its primary and key
secondary endpoints  urn:newsml:reuters.com:*:nGNX6HMyWK
    ** Osteoporosis is a disease characterized by low bone mass
and structural deterioration of bone tissue, which leads to
greater fragility and an increase in fracture risk
    ** Subjects receiving the 2.5 mg dose of EB613 showed
significant dose-related increases in bone mineral density (BMD)
at the lumbar spine, total hip, and femoral neck at 6 months
    ** Subjects receiving the 2.5 mg dose of EB613 for 6 months
also had a significant placebo adjusted increase of 3.78% in
lumbar spine BMD (p<0.008)
    ** Co also highlighted that an End of Phase 2 meeting with
U.S. FDA to review the EB613 development program is anticipated
in the coming months
    ** Up to Tuesday's close, stock has nearly tripled in value
this year

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))